Prevalence of Mast Cell Activation Syndrome in Patients With EDS With Digestive Disorders

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-09-28

Study Completion Date

2026-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to confirm the association between hypermobile Ehlers Danlos syndrome (hEDS) and mast cell activation syndrome (MCAS) in patients with digestive disorders managed in allergology departments.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comprehensive Assessment of Nutrition and Dietary Intervention in Hypermobile Ehlers Danlos Syndrome

NCT05148039

Hypermobile Ehlers-Danlos Syndrome Irritable Bowel Syndrome Functional Gastrointestinal Disorders

COMPLETED NA

Association Between Asthma and Food Allergy

NCT02884583

Food Allergy Suspected Food Allergy Proved

UNKNOWN NA

Importance and Association of Gut Microbiota and Biochemical Metabolites on Children Allergic Disorder

NCT05442658

Allergic Disorder Food Hypersensitivity Food Allergy in Children

COMPLETED

National, Multicenter, Retrospective, Prospective Study to Evaluate Pediatric Gastrointestinal Eosinophilic Disorders

NCT05219903

Eosinophilic Gastrointestinal Disorders Eosinophilic Esophagitis Eosinophilic Gastritis or Gastroenteritis +1 more

RECRUITING

A Multicentre French Prospective Study of Children With Food Protein Induced Enterocolitis Syndrome in Its Acute Form

NCT05528900

Food Protein Induced Enterocolitis Syndrome (FPIES)

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ehlers Danlos Hypermobile Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Determine the presence of mast cell activation syndrome

Mast cell activation syndrome will be confirmed if the following three conditions are met (according to Valent et al, 2012) :

* At least two clinical signs compatible with MAS before the first consultation (V1)
* Improvement of symptoms on antihistamines within 2 months of initiation of treatment
* Significant increase in tryptase during crisis

Mast cell activation syndrome will be possible if :

* At least two clinical signs consistent with MAS before the first consultation (V1)
* Improvement of symptoms with antihistamines within 2 months of initiation of treatment
* No significant increase in tryptase during crisis In all other cases, mast cell activation syndrome is unlikely.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* with hypermobile Ehlers Danlos syndrome
* with digestive disorders
* 14 years of age or older (minimum age for the MOS-SF 36 questionnaire)
* able to answer the questionnaires
* whose participation in a day hospital at Saint Vincent de Paul dedicated to the assessment of "functional digestive pain" is planned
* who do not object to the use of their health data for research purposes

Additional criteria for minors :

\- No objection to the use of health data for research purposes by parents/guardians

Exclusion Criteria

* under guardianship or curatorship
* having taken a long-term high-dose antihistamine treatment (H1 or H2) during the last two months, according to the following thresholds :

* Desloratadine (\>5 mg/jour)
* Bilastine (\>20 mg/jour)
* Cetirizine (\>20 mg/jour)
* Ebastine (\>10 mg/jour)
* Fexofenadine (\>150 mg/jour)
* Levocetirizine (\>5 mg/jour)
* Loratadine (\>10 mg/jour)
* Exocetiridine (5 mg/jour)
* Mizolastine (\>10 mg/jour)
* Rupatadine (\>10 mg/jour)
* Polaramine (\>10 mg/jour)
* Oxomemazine (\>2 mg/jour)
* Hydroxyzine (\>25 mg/jour)
* Doxylamine (\>15 mg/jour)
* Cimetidine (\>200 mg/jour)
* Patients deprived of liberty, pregnant or nursing women

Minimum Eligible Age

14 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No